# Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

> **NCT01753570** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 74 (actual)

## Conditions studied

- Chronic Hepatitis C(CHC)

## Interventions

- **DRUG:** MP-424
- **DRUG:** RBV(24 weeks)
- **DRUG:** IFN beta(24 weeks)
- **DRUG:** RBV(48 weeks)
- **DRUG:** IFN beta(48 weeks)

## Key facts

- **NCT ID:** NCT01753570
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01753570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01753570, "Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01753570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*